No Detail Found!

Is Lactulose Plus Rifaximin Better Than Lactulose Alone in the Management of Hepatic Encephalopathy?.

Author(s)
Nauman Ismat Butt Medical Unit II, Jinnah Hospital, Lahore, Pakistan
Usman Ismat Butt Surgical Unit II, Services Hospital, Lahore, Pakistan
Aniqa Anser Tufail Khan Kakar Medical Unit, University of Lahore Teaching Hospital, Lahore, Pakistan
Tashia Malik Medical Unit II, Jinnah Hospital, Lahore, Pakistan
Arif Mahmood Siddiqui Medical Unit II, Jinnah Hospital, Lahore, Pakistan
Abstract
Objective: To compare the efficacy of lactulose plus rifaximin with efficacy of lactulose alone in the treatment of hepatic encephalopathy. Study Design: A randomized controlled trial. Place and Duration of Study: Department of Medicine, Jinnah Hospital, Lahore, from December 2014 to June 2015. Methodology: All patients who presented with hepatic encephalopathy due to decompensated chronic liver disease were randomly divided into two groups of 65 patients each. One group was given 30 ml thrice daily lactulose alone and the other lactulose plus rifaximin 550 mg twice daily for 10 days. Informed consents were taken from the participants' attendants. Grades II-IV hepatic encephalopathy was noted according to West-Haven Classification. All subjects were followed until 10 days after admission. Results: The mean age of patients was 56.06 +11.2 years, among which 46.9% were females and 53.1% were males. After ten days of follow-up, reversal was seen in 58.46% in lactulose alone group and 67.69% in lactulose plus rifaximin group (Chi-square p=0.276). Conclusion: There was no difference in effectiveness of lactulose plus rifaximin and lactulose alone in treatment of hepatic encephalopathy.
Publication Details
Page(s) 115-117
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 2, Year: 2018

Request the full text from PASTIC

References
FerenciP,LockwoodA,MullenK., 2002.Hepatic encephalopathy definition, nomenclature, diagnosis,Hepatology 35 716 -21
Lizardi-CerveraJ,AlmedaP,GuevaraL,UribeM., 2003.Hepatic encephalopathy: a review,Ann Hepatol 2 122 -30
LuniaMK,SharmaBC,SachdevaS., 2013.Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and lowgrade hepatic encephalopathy,Hepatol Int 7 268 -73
RiordanSM,WilliamsR, 1997.Treatment of hepatic encephalopathy,N Engl J Med 337 473 -9
BustamanteJ,RimolaA,VenturaPJ, 1999.Prognostic significance of hepatic encephalopathy in patients with cirrhosis,J Hepatol 30 890 -5
MortensenPB, 1992.The effect of oral administrated lactulose on colonic nitrogen metabolism and excretion,Hepatolgy 16 1350 -6
ClausenMR,MortensenPB, 1997.Lactulose, disaccharides and colonic flora,Clinical consequences. Drugs 53 930 -42
OjettiV,LauritanoEC,BarbaroF, 2009.Rifaximin pharmacology and clinical implication,Expert Opin Drug Meta Toxicol 5 675 -82
De'MeloRT,CharneskiL,HilasO, 2008.Rifaximin for the treatment of hepatic encephalopathy,Am J Health Syst Pharm 65 818 -822
Als-NielsenB,GluudLL,GluudC, 2004.Non absorbable disaccharides for hepatic encephalopathy: systemic review of randomized trials,BMJ 328 1046 -
GerardL,GareyKW,DuPontHL, 2005.Rifaximin: a non-absorbable rifamycin antibiotic for use in non-systemic gastrointestinal infections,Expert Rev Anti Infect Ther 3 201 -11
SharmaBC,SharmaP,LuniaMK,SrivastavaS,GoyalR,SarinSK, 2013.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy,Am J Gastroenterol 108 1458 -63
EltawilKM,LaryeaM,PeltekianK,MolinariM., 2012.Rifaximin vs conventional oral therapy for hepatic encephalopathy: A metaanalysis,World J Gastroenterol 18 767 -77
JiangQ,JiangXH,ZhengMH,JiangLM,ChenYP,WangL, 2008.Rifaximin versus non-absorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis,Eur J Gastroenterol Hepatol 20 1064 -70
NguyenMH,WhittemoreAS,GarciaRT,TawfeekSA,NingJ,LamS, 2004.Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis,Clin Gastroenterol Hepatol 2 820 -4
SanakaMR,OngJP,MullenKD, 2003.Challenges of designing hepatic encephalopathy treatment trials,Hepatology 38 527 -8
GluudLL,DamG,BorreM,LesI,CordobaJ,MarchesiniG, 2013.Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?,Metab Brain Dis 28 221 -5
StahlJ, 1963.Its diagnostic, prognostic, and therapeutic significance,Ann Intern Med 58 1 -24
ConnHO,LeevyCM,VlahcevicZR,RodgersJB,MaddreyWC,SeeffL, 1977.Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial,Gastroenterology 72 573 -83
0

Citations

0

Downloads

67

Views